The NUSTART Programme has been designed to comply with the Privacy Laws of Australia and New Zealand and is committed to managing personal information in an open, transparent and secure way.
GlaxoSmithKline Pty Ltd (GSK) has engaged Partizan Worldwide Pty Ltd (Partizan Worldwide) to administer the NUSTART Support Programme. In order to provide NUSTART Support Programme Services to you, Partizan Worldwide will collect and hold some of your personal information.
To participate in the NUSTART Programme, you need to enrol and consent to the NUSTART Support Programme Terms and Conditions. In order for the NUSTART Programme to provide you with program services, some personal information, such as your name, age, address and telephone number, as well as relevant treatment information will need to be collected.
If you choose not to provide the information requested, it may not be possible for the NUSTART Coordinator to contact you or provide programme services as part of the NUSTART Programme.
Sensitive personal information will be used by the NUSTART Programme Administrators to contact patients and Healthcare Professionals, create an enrolment record; and enter into the NUSTART Programme registries, databases and web based systems hosted in Australia and/or New Zealand.
Personal sensitive information provided may be disclosed by Partizan Worldwide to the patient’s nominated Healthcare Practitioner(s) or to third party individuals or organisations contracted or involved in the administration of the NUSTART Programme such as:
Should you experience an adverse event or product complaint, we will need to provide this to GSK, who may be required to report this, even if it has already been reported by you directly to a doctor, or the regulatory authorities.
As a sponsor, GSK has a responsibility to monitor the use of their products continually and record the safety of the medicine and the balance of its benefit and risk. GSK may disclose your de-identified personal or sensitive information to the relevant regulatory authorities solely for the purpose of, and to the extent required to, report such adverse event.
GSK, or a third party acting on their behalf, may contact a patient’s Healthcare Professional in order to collect further information related to an adverse event. Your de-identified personal information may be processed by GSK, its affiliated companies and GSK’s trusted third party suppliers outside New Zealand. GSK implement appropriate measures to ensure that your de- identified personal information remains protected and secure when it is transferred outside New Zealand, in accordance with applicable data protection and privacy laws.
De-identified information relating to a patient’s participation in the NUSTART Programme may also be collated into a report for GSK. GSK may use this information to:
GSK may also share de-identified information with its parent Company or its affiliates regarding how the Programme is working on an aggregated basis. This information does not identify patients individually. Any personal information collected by GSK will be handled in accordance with GSK’s privacy policy available at https://privacy.gsk.com/en-nz/privacy-notice/privacy-principles.
Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the NUSTART Programme) will retain the sensitive personal information collected for the period of your participation in the NUSTART Programme and after your participation in the Programme has ended for the purposes of reporting, audit and as required by law. Retention of sensitive personal information is also regulated by medical legislation. Any sensitive personal information relating to adverse event reporting must be retained for seven years after the finalisation of product commercialisation, discontinuation of development, out licensing or other action whereby GSK have no further requirement for monitoring safety of the product.
At your request, Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the NUSTART Programme) will update your personal information as it changes during the course of your participation in the NUSTART Programme.
Please contact the Privacy officer at Partizan Worldwide, 54 Victoria Street, McMahons Point, NSW 2060, Australia:
If you have any questions about your condition or treatment, please contact your treating healthcare professional.
If you have any questions about the NUSTART Programme, please call the programme coordinator on 0800 111 059, Monday to Friday 10am - 6pm NZDT.
TAPS: NP20117 NX-NZ-MPL-BRF-230011. Date of approval: November 2023. Date of Expiry: November 2025.